Teva confirmed that it had launched approximately 315 generic medicines and conducted 130 clinical trials throughout 2014. The company reiterated a target to launch 1,000 new generic medicines in 2016. Looking beyond 2016, the company has also indicated that it plans to launch some 1,500 generic medicines in 2017.

These are likely to span nearly every therapeutic area, although the disorders of the central nervous system and respiratory products could dominate. In addition, Teva confirmed that it was on target to launch a reported 27 speciality health products by 2019.